The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02236741

Enrollment

26814

Registered

2014-09-11

Start date

2009-11-30

Completion date

Unknown

Last updated

2014-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

Study to assess the risk of incident heart failure associated with the use of pramipexole compared with other dopamine agonists and additionally, to assess the risk of incident heart failure associated with the use of dopamine agonists in comparison with no use of dopamine agonist therapy

Interventions

DRUGMirapexin® (Sifrol®)

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 89 Years

Healthy volunteers

Inclusion criteria

* All patients between 40 and 89 years of age who received at least one prescription for anti-parkinsonian drugs during the period 1997-2009

Exclusion criteria

* Patients with a diagnosis of heart failure or with prescriptions for two or more among the digitalis, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blocker (ARB), and diuretic drug classes prior to cohort entry

Design outcomes

Primary

Measure	Time frame
Assessment of first-time clinical diagnosis of heart failure	150 months

Secondary

Measure	Time frame
Overall rate of heart failure	150 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026